Matrix Metalloproteinase-1 as an Independent Prognostic Biomarker in Epithelial Ovarian Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Elevated serum matrix metalloproteinase-1 (MMP-1) is a poor prognostic factor for ovarian cancer survival. Combining MMP-1 with CA125 may improve prognostic accuracy for patients.
Area Of Science
- Oncology
- Biomarker Discovery
- Cancer Prognostics
Background
- Ovarian cancer prognosis remains challenging.
- Identifying reliable prognostic biomarkers is crucial for patient management.
- Matrix metalloproteinase-1 (MMP-1) role in ovarian cancer requires further elucidation.
Purpose Of The Study
- To determine if matrix metalloproteinase-1 (MMP-1) expression is a poor prognostic factor in ovarian cancer.
- To investigate the prognostic value of both serum and tumor tissue MMP-1 levels.
Main Methods
- Retrospective analysis of 74 ovarian cancer patients.
- Measurement of preoperative serum MMP-1 via ELISA.
- Immunohistochemical evaluation of tumor tissue MMP-1 expression.
- Kaplan-Meier and Cox regression analyses for survival outcomes.
Main Results
- Elevated serum MMP-1 concentration independently predicted poor overall survival (OS).
- Tumor tissue MMP-1 expression did not independently predict OS or progression-free survival (PFS).
- Serum MMP-1 levels positively correlated with Cancer Antigen 125 (CA125).
Conclusions
- Serum MMP-1 concentration shows potential as a poor prognostic biomarker in ovarian cancer.
- Combining serum MMP-1 with CA125 may enhance prognostic assessment for ovarian cancer patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.